Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)

NEXT STORY
Résultats positifs de la phase 2b pour le mélanome en 2e ligne
PREV STORY
Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Treatment with Novartis’ Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation

Ultibro® Breezhaler® provided significant improvements in cardiac and lung function in COPD patients with ...

author_avatar
NASDAQ Market News

Cytokinetics Announces Additional Results From COSMIC-HF Presented at ACC.17

SOUTH SAN FRANCISCO, Calif., March 20, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today ...

author_avatar
NASDAQ Market News

Global Avian Influenza (Infectious Disease) Drugs Development Market Report 2021: Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type

author_avatar
NASDAQ Market News